

1 **Associations between measures of social distancing and SARS-CoV-2**
2 **seropositivity: a nationwide population-based study in the Netherlands**

3

4 Eric R.A. Vos¹, Michiel van Boven¹, Gerco den Hartog¹, Jantien A. Backer¹, Don Klinkenberg¹,
5 Cheyenne C.E. van Hagen¹, Hendriek Boshuizen¹, Rob S. van Binnendijk¹, Liesbeth Mollema¹, Fiona
6 R.M. van der Klis¹, Hester E. de Melker¹

7

8 ¹Centre for Infectious Disease Control, National Institute for Public Health and the Environment
9 (RIVM), Antonie van Leeuwenhoeklaan 9, 3720 MA Bilthoven, the Netherlands.

10

11 **KEYWORDS:** COVID-19 pandemic; SARS-CoV-2 seroprevalence; social distancing; transmission; the
12 Netherlands

13

14 **RUNNING TITLE:** Effect of social distancing on SARS-CoV-2

15

16

17

18

19

20

21 **CONTACT INFORMATION:**

22 Corresponding author: Eric R.A. Vos; Address: Antonie van Leeuwenhoeklaan 9, 3720 MA Bilthoven,
23 the Netherlands; Email: eric.vos.02@rivm.nl.

24 Alternate corresponding author: Hester E. de Melker; Antonie van Leeuwenhoeklaan 9; 3720 MA
25 Bilthoven; the Netherlands; Email: hester.de.melker@rivm.nl.

26 **ABSTRACT**

27 This large nationwide population-based seroepidemiological study provides evidence on the
28 effectiveness of physical distancing (>1.5m) and indoor group size reductions on SARS-CoV-2
29 infection. Additionally, young adults seem to play a significant role in viral spread, opposed to
30 children up until the primary school age with whom close contact is permitted.

31 **INTRODUCTION**

32

33 The coronavirus disease 2019 (COVID-19) pandemic is an unprecedented global crisis. Stringent
34 measures to suppress the spread of its causative agent severe acute respiratory syndrome
35 coronavirus-2 (SARS-CoV-2) have been implemented to reduce incidence of disease and prevent
36 health systems from becoming overwhelmed. Assessment of the impact of social-distancing
37 measures is vital for informing public health decisions, particularly since the worldwide availability of
38 vaccines is still very limited in this phase.

39

40 In the Netherlands, the first case of COVID-19 was reported on February 27, 2020. Key governmental
41 interventions implemented since mid-March, 2020, included: keeping physical distance ($\geq 1.5\text{m}$) for
42 those aged >12 years, whereas close contact between 13-17 year-olds was permitted; closure of
43 schools, restaurants/bars/cafés, cultural institutions, sport facilities; working from home if possible;
44 prohibition of contact professions; closure of nursing homes to visitors; and reducing group sizes. In
45 May, primary schools and daycare were re-opened, and contact professions were allowed to
46 resume. From June onwards, measures were further relaxed, while adhering to physical distancing
47 measures.

48

49 Seroprevalence of antibodies against SARS-CoV-2, acquired from validated laboratory assays and
50 well-designed population-based studies, provide an unbiased indicator of cumulative infection [1, 2].

51 In combining seroprevalence with questionnaire data, the current nationwide population-based
52 study (PIENTER-Corona, PICO) [3] – set-up after the first epidemic wave in the Netherlands in June,
53 2020 – enabled us to identify risk factors for infection to support assessment of the impact of
54 globally-applied social distancing measures.

55 **METHODS**

56

57 Randomly-selected participants of all age groups from the first PICO-serosurvey in April, 2020 [3, 4],
58 were invited for the current study in June and 2,317 enrolled. To enhance countrywide geographical
59 coverage, and given the low anticipated seroprevalence, this cohort was supplemented with an
60 additional sample of 4,496 randomly sampled participants ($n_{\text{total}}=6,813$) (**Supplement-p3-4**).

61 Participants were requested to collect a fingerstick blood sample and return it by mail. An (online)
62 questionnaire was completed on potential SARS-CoV-2 exposure (number and age group of non-
63 household close contacts (<1.5m) the day before filling out the questionnaire, attendance of indoor
64 meetings with >20 persons, nursing home visits, working from home last week, profession, close
65 contact (voluntary) work with patients/clients and children, and household size); and
66 sociodemographic characteristics (sex, age, ethnic background, religion, educational level, postal
67 codes were used to determine geographical sites).

68

69 Quantitative measures of serum IgG antibodies against SARS-CoV-2 Spike-S1 antigen were derived
70 via a validated multiplex-immunoassay [5]. Based on low anticipated seroprevalence [3], we aimed
71 for a specificity of 99.9% to keep false positive rates to a minimum. Mixture model analyses (using a
72 validation panel as prior distribution) showed that such specificity could be obtained (at a cut-off for
73 seropositivity of 0.04 log(AU)/mL) with associated sensitivity of 94.3% (95% confidence interval (CI)
74 90.6-96.7) (**Supplement-p6-15**). Applying this cut-off, all seroprevalence estimates (and 95% CIs) for
75 the general Dutch population took into account the survey design, included weighting factors to
76 match the distribution of the general Dutch population (based on sex, age, ethnic background and
77 degree of urbanization; **Supplement-p6**), and were controlled for test characteristics subsequently
78 [6, 7]. Smooth age-specific seroprevalence was modelled with B-splines (second degree, three
79 percentile-placed internal knots, following lowest Akaike's Information Criteria (AIC)).

80

81 Risk factors for seropositivity were identified using random-effects logistic regression – taking into
82 account municipality as a unit of clustering. In the main analysis, all participants without missing
83 data for the tested determinants were included (n=6,331). Odds ratios (OR) and 95% CIs were
84 derived from univariable analyses, and two-way interactions with age were tested for significance.
85 Variables with an overall p<0.15 were tested in multivariable analysis, in which stepwise-backward
86 selection was applied yielding a final model including only independent risk factors (based on lowest
87 AIC). Sensitivity analyses were performed applying forward selection; and by testing models without
88 religion (n=6,487) – as this variable comprised the most missing values – without educational level
89 (n=6,339) and without non-household contact data (n=6,338) – the latter two to test potential
90 associations with profession.

91

92 Analyses were performed using Stan v.2.21 (mixture modelling), and SAS v.9.4 (SAS Institute Inc.,
93 USA). The study was approved by the Medical Ethics Committee MEC-U (Clinical Trial Registration
94 NTR8473) and all participants provided written informed consent.

95 **RESULTS**

96

97 Median inclusion date was June 14, 2020 (range: June 9–Augustus 24; 90% was enrolled by June 22)
98 (note: sociodemographic characteristics available from non-responders were compared to
99 responders and shown in **Supplement–p4-5**). The cohort comprised 55% women and regions were
100 equally represented following population size (**Supplement–p5-7**). Half of the participants reported
101 to have had ≥ 2 non-household close contacts the day before filling out the questionnaire. Since the
102 start of the epidemic, one quarter had attended an indoor meeting with >20 persons, and 8% had
103 visited a nursing home. Among 18-66 year-olds, 36% (voluntarily) worked in close contact with
104 clients/patients, 18% was a healthcare worker, and 40% had been (partly) working from home last
105 week.

106

107 After the first epidemic wave, overall seroprevalence in the Dutch population was 4.5% (95% CI 3.8-
108 5.2). No difference was observed between sexes and ethnic backgrounds. Estimates were low (0-2%)
109 in children aged 1-12 years, high (9%) in young adults in their early twenties, and 4-7% in individuals
110 ≥ 35 years (**Figure1A**). Low urbanized areas were hit hardest, predominantly in the South-East (up till
111 16%) (**Supplement–p16**).

112

113 All potential risk factors for seropositivity tested in univariable analyses are shown in **Figure1B** (and
114 for age in **Supplement–p16**). Close contact (voluntary) work with children was not associated. Also,
115 work with clients/patients and total number of non-household close contacts did not remain in the
116 final model. Social distancing-related risk factors in the multivariable model included (**Figure1C**):
117 non-household close contacts with $\geq 50\%$ persons ≥ 10 years as compared to no contacts, whereas
118 close contact with $\geq 50\%$ children aged <10 years was not statistically significantly associated (see
119 also **Figure1E**); attending indoor meetings with >20 persons; working in a nursing home (rather than
120 a visitor), increased household size; and age, with low adjusted odds in children ≤ 12 years, whilst

121 over 2.5 times higher odds in adults aged 18-30 and ≥ 50 years as compared to 12-year-olds
122 (**Figure1D**). Sensitivity analyses yielded similar results.

123 **DISCUSSION**

124

125 Here, we provide evidence from a large population-based study on the effectiveness of physical
126 distancing (>1.5m) as well as indoor group size reductions on SARS-CoV-2 infection, and these data
127 substantiate policy of allowing close contact between teachers and children in primary school.

128

129 Our results on physical distancing are in line with the few previous reports mostly derived from
130 healthcare settings and households [8]. Seroprevalence rates were low in children aged ≤ 12 years
131 despite close contact, and similar to observations from other European countries with comparable
132 nationwide estimates [1, 9]. Interestingly, the likelihood of infection among persons in close contact
133 with children was not statistically significantly increased, most likely indicating a low contribution in
134 transmission, as suggested previously [10-13]. On the other hand, particularly young adults, who
135 engage in relatively more social interaction as opposed to older age groups [14] and often living in
136 larger (student) households, most probably play an increased role. Applying physical distancing
137 measures within households may not always be feasible, however stressing its relevance in outbreak
138 management could help to reduce (ongoing) transmission. Further, like in ample other countries
139 [15], these data underline the increased risk of infection among nursing home workers. Hence, while
140 working with the most vulnerable, this requires specific attention.

141

142 Our study has strengths and limitations. Strength is that our study provides a large population
143 sample covering a full age-range from young to old, combining a sound indicator of prior infection,
144 i.e., seropositivity, to extensive questionnaire data. Also, samples could be classified accurately since
145 antibodies were measured with a highly specific and sensitive immunoassay. Limitations include the
146 relatively low response rate, which might have introduced potential selection bias, e.g., of relatively
147 more health-conscious individuals adhering to social distancing measures. Further, some variables

148 might be proxies of risk of viral exposure, e.g., on contacts, thus associations should be interpreted
149 with care as they may not reflect causal effects.

150

151 In conclusion, these results underscore the effectiveness of the social distancing-related measures to
152 reduce SARS-CoV-2 transmission in an era of limited availability of vaccines. Additionally, our data
153 suggest a diminished role of young children in viral spread, which may justify decisions to keep
154 primary schools open, while young adults seem to play a more substantial role.

155 **ACKNOWLEDGMENTS:** We gratefully acknowledge the participants of the current study. Moreover,
156 this study would not have been possible without the instrumental contribution of colleagues from
157 the National Institute of Public Health and Environment (RIVM), more specially the department of
158 Immunology of Infectious Diseases and Vaccines (IIV) (regarding logistics and laboratory analyses),
159 and the department of Epidemiology and Surveillance (EPI) (concerning logistics, and methodological
160 and statistical insights). Furthermore, we would also like to thank Maarten Schipper for performing
161 the sampling, and Susan van den Hof (EPI department head) for reviewing the manuscript.

162

163

164 **REFERENCES**

- 165 1. Rostami A, Sepidarkish M, Leeflang M, et al. SARS-CoV-2 seroprevalence worldwide: a
166 systematic review and meta-analysis. *Clinical Microbiology and Infection*.
- 167 2. Koopmans M, Haagmans B. Assessing the extent of SARS-CoV-2 circulation through
168 serological studies. *Nature Medicine*. 2020 2020/07/27.
- 169 3. Vos ERA, den Hartog G, Schepp RM, et al. Nationwide seroprevalence of SARS-CoV-2 and
170 identification of risk factors in the general population of the Netherlands during the first epidemic
171 wave. *Journal of Epidemiology and Community Health*. 2020:jech-2020-215678.
- 172 4. Verberk JDM, Vos RA, Mollema L, et al. Third national biobank for population-based
173 seroprevalence studies in the Netherlands, including the Caribbean Netherlands. *BMC Infect Dis*.
174 2019 May 28;19(1):470.
- 175 5. den Hartog G, Schepp RM, Kuijer M, et al. SARS-CoV-2–Specific Antibody Detection for
176 Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence. *The*
177 *Journal of Infectious Diseases*. 2020.
- 178 6. Rogan WJ, Gladen B. Estimating prevalence from the results of a screening test. *Am J*
179 *Epidemiol*. 1978 Jan;107(1):71-6.

- 180 7. Lang Z, Reiczigel J. Confidence limits for prevalence of disease adjusted for estimated
181 sensitivity and specificity. *Prev Vet Med.* 2014 Jan 1;113(1):13-22.
- 182 8. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ. Physical distancing, face masks,
183 and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a
184 systematic review and meta-analysis. *Lancet.* 2020 Jun 27;395(10242):1973-87.
- 185 9. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-
186 COVID): a nationwide, population-based seroepidemiological study. *The Lancet.*
- 187 10. Davies NG, Klepac P, Liu Y, et al. Age-dependent effects in the transmission and control of
188 COVID-19 epidemics. *Nature Medicine.* 2020 2020/08/01;26(8):1205-11.
- 189 11. van der Hoek W, Backer JA, Bodewes R, et al. [The role of children in the transmission of
190 SARS-CoV-2]. *Ned Tijdschr Geneeskd.* 2020 Jun 3;164.
- 191 12. Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 Infection Among Children
192 and Adolescents Compared With Adults: A Systematic Review and Meta-analysis. *JAMA Pediatrics.*
193 2020.
- 194 13. Ludvigsson JF. Children are unlikely to be the main drivers of the COVID-19 pandemic – A
195 systematic review. *Acta Paediatrica.* 2020;109(8):1525-30.
- 196 14. Backer JA, Mollema L, Vos ERA, et al. The impact of physical distancing measures against
197 COVID-19 transmission on contacts and mixing patterns in the Netherlands: repeated cross-sectional
198 surveys in 2016/2017, April 2020 and June 2020. *Eurosurveillance* [in press].
- 199 15. Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among front-line health-care
200 workers and the general community: a prospective cohort study. *The Lancet Public Health.*
201 2020;5(9):e475-e83.

202 **FUNDING:** This work was supported by the Ministry of Health, Welfare and Sports (VWS), the
203 Netherlands [grant number not applicable]. The views expressed are those of the authors and not
204 necessarily those of VWS or the RIVM. The funder played no role in study design; in the collection,
205 analysis, and interpretation of data; in the writing of the report; or in the decision to submit the
206 paper for publication. The corresponding author had full access to all the data in the study and had
207 final responsibility for the decision to submit for publication.

208


209 **ETHICAL APPROVAL:** This study protocol was approved by the Medical Ethics Committee MEC-U, the
210 Netherlands (Clinical Trial Registration NTR8473), and conformed to the principles embodied in the
211 Declaration of Helsinki.

212

213 **FIGURE LEGEND:**


214 **Figure1: A.** Shows the weighted smooth age-specific SARS-CoV-2 seroprevalence with 95%
215 confidence envelope in the general population of the Netherlands after the first epidemic wave. **B**
216 **and C** display the risk factor analyses for SARS-CoV-2 seropositivity. Number (and %) of total
217 participants per potential risk factor-category are provided as well as the number (and %) of
218 seropositive participants (pos.), and overall P-values. Forest plots are shown of crude odds ratios
219 (OR) for univariable analyses (**B**) and adjusted odds ratios (aOR) for the multivariable analysis (**C**),
220 and depicted by squares and 95% confidence intervals (95% CIs) with lines: those in red are
221 significantly associated with seropositivity and those in blue are non-significant. Age was included
222 with a flexible (spline) function. Time window of attending indoor meetings with > 20 persons and
223 visiting a nursing home concerned the beginning of the epidemic in the Netherlands (February 27,
224 2020) until the day of filling out the questionnaire or until closure (for visitors) of nursing homes
225 (March 20, 2020), respectively. Nature and number of non-household close contacts yesterday, and
226 working from home last week, concerned the day or week, respectively, before filling out the
227 questionnaire. Receiver operating characteristic curve analysis of the multivariable model yielded an

228 area under the curve (as a measure of goodness-of-fit) of 0.72. **D.** shows the aOR with 95%
229 confidence envelope for age derived from the multivariable model, with 12 year as reference
230 category. **E.** displays SARS-CoV-2 seropositivity (and 95% confidence intervals) by number and nature
231 of non-household close contact the day before filling out the questionnaire. Nature of non-
232 household close contact was defined as the proportion of non-household close contacts with
233 children aged < 10 years of the total number of non-household close contacts.

A


B


Univariable models: risk factors for SARS-CoV-2 seropositivity




C

Multivariable model: risk factors for SARS-CoV-2 seropositivity



D

E

Associations between measures of social
distancing and SARS-CoV-2 seropositivity:
a nationwide population-based study
in the Netherlands

Supplementary Information

Eric R.A. Vos, Michiel van Boven, Gerco den Hartog,
Jantien A. Backer, Don Klinkenberg, Cheyenne C.E. van Hagen,
Hendriek Boshuizen, Rob S. van Binnendijk, Liesbeth Mollema,
Fiona R.M. van der Klis, Hester E. de Melker

January, 2021

Contents

1	Introduction	3
2	Sampling	3
3	Non-response and weighting	4
4	Data	6
5	Mixture model	7
6	Estimation	8
7	Binary classification	12
8	Logistic regression	15

1 Introduction

In this supplement we detail our sampling strategy, provide information on non-response rates, and explain how we have included post-stratification weighting in the analyses. The risk factor analyses in the main text use logistic regression based on binary classification of the data (seronegative versus seropositive). Here, we also provide an underpinning of this classification using a two-component mixture model. In this model, samples are not rigidly classified as either seronegative or seropositive, but belong to either the negative or positive component with certain probability [1, 2]. As the probability of seropositivity may depend on age, we model the mixing parameter (i.e. the probability of seropositivity, or seroprevalence) with an age-dependent penalized spline [3]. We fit the model to antibody concentration measurements from the population sample described in the main text while incorporating information from a test panel of proven negative and positive samples [4]. Subsequently, we derive test characteristics (sensitivity, specificity) for various cut-offs, showing that the binary classification used in the main text performs well. In a final step we present additional results for the weighted seropositivity estimates by municipal health services, and for the age-specific odds of seropositivity.

2 Sampling

The current cohort includes persons who had participated in our earlier SARS-CoV-2 serosurveillance study in March, 2020 (sample 1) and an additional nationwide sample (sample 2). Details on the first sample have been described previously [5, 6]. In this previous study, 2,634 participants had been included. Anticipating a 10% drop-out rate from the first study, and given the low estimated seroprevalence in the first study (2.8%), we aimed to increase the overall power of the study. Hence, the initial cohort was supplemented with an additional sample of randomly sampled participants from the Dutch population

registry as of May, 2020.

For this second sample, persons were randomly drawn from five regions with roughly similar population size (North: provinces of Groningen, Friesland, Drenthe and Overijssel; Mid-West: provinces of Flevoland and Noord-Holland; Mid-East: provinces of Gelderland and Utrecht; South-West: provinces of Zuid-Holland and Zeeland; South-East: provinces of Noord-Brabant and Limburg), and from 17 pre-defined age groups (1-4, 5-9, 10-14, 15-19, 20-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80-89 years).

A total sample size of 6,400 participants, i.e. with an average of 380 participants per age group, would enable us to estimate an overall and age-specific seroprevalence with a precision of 1.25% and 5%, respectively. Following previous experience, we anticipate a response rate of at least 15%. Hence, for the additional sample, we randomly selected 27,200 persons from the population registry, of which 26,854 remained eligible for participation after an initial screening.

3 Non-response and weighting

All randomly-selected persons who were invited in the first serological study were also invited for the current study. Of these, 2,317 participated in the current study. This cohort was subsequently supplemented with an additional sample (as described above). Specifically, we invited 26,854 randomly-selected persons of which 4,496 participated, resulting in an overall number of 6,813 participants. Table S1 shows the number of participants and response rates, stratified by sex, age group, region, and ethnic background. See main text for details and discussion.

Table S1. Overview of the study data. Ethnicity is missing for 16 invited persons.

		Non-responder		Responder		Total
		N	%	N	%	31,780
Total		24,967	78.6	6,813	21.4	
Sex	Man	12,609	50.5	3,042	44.7	15,561
	Women	12,358	49.5	3,771	55.4	16,129
Age	1-4	1,740	7.0	220	3.2	1,960
	5-9	1,637	6.6	285	4.2	1,922
	10-14	1,567	6.3	319	4.7	1,886
	15-19	1,591	3.4	304	4.5	1,895
	20-24	1,542	6.2	300	4.4	1,842
	25-29	1,779	7.1	398	5.8	2,177
	30-34	1,293	5.2	369	5.4	1,662
	35-39	1,519	6.1	408	6.0	1,927
	40-44	1,439	5.8	448	6.6	1,887
	45-49	1,423	5.7	457	6.7	1,880
	50-54	1,365	5.5	548	8.0	1,913
	55-59	1,323	5.3	544	8.0	1,867
	60-64	1,226	4.9	591	8.7	1,817
	65-69	1,250	5.0	626	9.2	1,876
	70-74	1,326	5.3	501	7.4	1,827
75-79	1,410	5.7	134	2.0	1,752	
80-90	1,537	6.2	153	2.3	1,690	
Region	North	5,029	20.1	1,357	19.9	6,386
	Mid-West	4,957	19.9	1,211	17.8	6,168
	Mid-East	4,825	19.3	1,469	21.6	6,294
	South-West	5,060	20.3	1,248	18.3	6,308
	South-East	5,096	20.4	1,528	22.4	6,624
Urbanization degree	High	6,038	24.2	1,319	19.4	7,357
	Middle	7,670	30.7	2,101	30.8	9,771
	Low	11,259	45.1	3,393	49.8	14,652
Ethnic background	Dutch	18,598	74.5	5,996	88.0	24,594
	Non-Dutch Western	2,389	9.6	512	7.5	2,901
	Non-Western	3,964	15.9	305	4.5	4,269

Post-stratification weights are assigned to each participant to standardize seroprevalence estimates, using census data of the Netherlands from January 2020. Since our cohort consists of two samples, weights are calculated for each sample separately. Per study sample, weights are assigned to each participant based on their membership to specific census strata (in total 112): for Dutch ethnic background, strata are designed for age group (1-4, 5-9, 10-14, 15-19, 20-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-90 years), urbanization level (high, middle, low), and sex; and for other ethnicity groups strata were based on age group (1-9, 10-34, 35-59, 60-90 years) and sex.

Subsequently, post-stratification weights are defined as the proportion of each stratum represented in the Dutch population divided by the analogous proportion in the study sample. Specifically, participant weights w_{ij} for participants in stratum i and study j are calculated as

$$w_{ij} = \frac{\frac{X_i}{N}}{\frac{x_{ij}}{n_j}},$$

where X_i is the total number of persons in stratum i , N is the total population size (i.e. the Netherlands), x_{ij} is the number of participants in stratum i in study sample j , and n_j is number of participants in sample j .

4 Data

Figure S1 shows the regional distribution of samples, and Figure S2 shows the antibody concentration measurements by age. For the analyses, we also include a validation panel that has been used for validation of the assay [4]. Specifically, we take a set of 384 samples from uninfected persons that had been drawn from the Dutch population before the pandemic, and a set of 115 proven SARS-CoV-2 infections with mild to severe disease [4]. Mean and standard deviation of the (log-transformed) measurements are $\mu_{\text{uninfected}} = -2.3$ (arbitrary units) and $\sigma_{\text{uninfected}} = 1.0$ for the uninfected group, and $\mu_{\text{infected}} = 3.0$ and $\sigma_{\text{infected}} = 2.1$ for the infected group.




Figure S1. Regional distribution of samples. Notice that the western part of the Netherlands is the most densely populated area and also has large number of samples, thus attaining good population coverage.

5 Mixture model

Survey participants are assumed to be either seropositive or seronegative. These two classes are characterized by distributions for antibody measurements, denoted by f_{neg} and f_{pos} and specified by parameters θ_{neg} and θ_{pos} . Further, the mixing parameter (probability of seropositivity) depends on age and is denoted by $p(a)$. For $n = 6,813$ participants, the set of participant ages and observed measurements are given by $\mathbf{a} = (a_k)$ and $\mathbf{x} = (x_k)$ ($k = 1, \dots, n$), respectively. Throughout we use normal distributions for the components of the mixture of




Figure S2. Overview of the data. Shown are (log-transformed) antibody concentrations of all 6,813 samples in the national sample as function of age. Here, samples are classified as seronegative below the cut-off of 0.04 ($\log(\text{AU})/\text{mL}$) (blue) and as seropositive above the cut-off (red).

the log-transformed data, so that $\theta_{\text{neg}} = (\mu_{\text{neg}}, \sigma_{\text{neg}})$ and $\theta_{\text{pos}} = (\mu_{\text{pos}}, \sigma_{\text{pos}})$, while the mixing parameter is modelled with a Bayesian penalized-spline using cubic basis functions and first order penalization [7, 8]. Throughout, we consider the age range $[0, 100]$ years, placing knots at 10-year intervals (11 knots in total), so that the total number of basis functions is 13 [7, 8].

6 Estimation

Parameters are estimated in a Bayesian framework using Hamiltonian Monte Carlo, implemented in Stan [9]. To improve performance at low prevalence, we employ a logistic transformation for the age-specific prevalence.

Prior distributions for the means and standard deviations of the seronegative and seropositive components are based on the uninfected and infected samples from the validation set. As the uninfected set is obtained from random samples

from the Dutch population in 2006/2007 and 2016/2017 as well as a panel comprising cases with influenza-like illness, and the seropositive set contains cases with symptoms of disease and may be less representative of cases in the population, we take informative prior distributions for the parameters of the seronegative component, a weakly informative prior distribution for the mean of the seropositive component, and provide no explicit prior distribution for the standard deviation of the seropositive component. Specifically, we take

$$\mu_{\text{neg}} \sim \mathcal{N}(\mu_{\text{uninfected}}, 0.01)$$

$$\sigma_{\text{neg}} \sim \mathcal{N}(\sigma_{\text{uninfected}}, 0.1)$$

$$\mu_{\text{pos}} \sim \mathcal{N}(\mu_{\text{infected}}, 0.5) .$$

For the spline smoothing parameter (RWvar) we take an inverse gamma distribution [8],

$$\text{RWvar} \sim \text{inverse gamma}(1, 0.0005) ,$$

and for the weights of the spline base functions w_i ($i = 1 \dots 13$), we take

$$w_i \sim \mathcal{N}(0, 4) ,$$

where it should be noted that the prior weights are defined on the logistic scale.

Table S2. Parameter estimates (selected posterior quantiles) with selected convergence diagnostics.

Parameter	\widehat{R}	n_{eff}	2.5%	50%	97.5%
μ_{neg}	0.997	1071	-2.311	-2.297	-2.284
σ_{neg}	0.997	964	0.742	0.756	0.770
μ_{pos}	0.996	1066	1.967	2.168	2.336
σ_{pos}	1.003	1126	1.216	1.339	1.501
RWvar	1.000	1030	0.008	0.042	0.169

Results from properly converged chains are obtained within hours (using 10 cores on our servers). Estimates for the parameters defining the mixing distribution and the spline smoothing parameter are given in Table S2, together with




Figure S3. Data and model fit. Shown are the data (gray histograms) and fit of the mixture model (blue: seronegative component; red: seropositive component). The age-specific prevalence is modelled with a penalized spline, and the mixing distributions are weighted with the overall posterior probability of infection. Shown are 1,000 samples from the posterior distribution.

convergence diagnostics \hat{R} and n_{eff} [9]. In a sensitivity analysis we have re-run the fitting procedure with uninformative prior distributions (only assuming that $\mu_{\text{pos}} > \mu_{\text{neg}}$). These analyses yield virtually identical results (not shown).

Figure S3 gives a visualisation of the data (gray histograms) and model fit (colored lines), suggesting good agreement between the two. Notice also that overlap between the negative and positive component is small which bodes well for efforts to distinguish seronegative from seropositive samples. To further investigate the implications of the analyses, Figure S4 shows the estimated probability of infection as function of antibody concentration. Here, the probability of infection calculated as the estimated positive density (at a certain concentration) divided by the sum of the positive and negative densities (at that concentration) [1]. The figure shows that, in the absence of information on age-specific preva-

lence, the estimated probability of infection is close to 0 for concentrations of -1 ($\log(\text{AU})/\text{mL}$) and lower, and close to 1 at concentrations of 0 ($\log(\text{AU})/\text{mL}$) and higher.




Figure S4. Estimated probability of seropositivity. Shown are estimated probabilities of seropositivity as function of the (log-transformed) antibody concentration. No weighting for prevalence is applied. Shown are 1,000 samples from the posterior distribution.

In a next step we estimated the probability of seropositivity for each of the $n = 6,813$ samples. Here we weighted the posterior seropositive density by the posterior prevalence, and the posterior seronegative density by 1 minus the posterior prevalence, and applied the same procedure as in Figure S4. The figure shows that for the majority of samples (6,722), the posterior median for the probability of infection is either low (< 0.05 , 6,437 samples) or high (> 0.95 , 285 samples), indicating that only for a small minority of samples (< 100) classification would not be straightforward. This is a robust result that also holds when using less informative priors or when including a random effect at the municipality level (not shown). It is due to the clear separation of the negative and positive components in the analyses (Figure S3).




Figure S5. Estimated probability of seropositivity. Shown are estimated probabilities of seropositivity for each of the 6,813 samples as function of age. Estimates are weighted with age-specific prevalence. Dots and whiskers represent posterior medians and 95% credible intervals, respectively. Notice that the posterior probability of seropositivity (i.e. posterior median) is either very low (< 0.05) or very high (> 0.95) for the majority of samples ($> 98\%$).

7 Binary classification

The above results show that for the majority of samples there is limited uncertainty as to whether they should be classified as seronegative or seropositive. Therefore, we feel confident that reliable binary classification of the samples is feasible. Here, we investigate the optimal cut-off value for such binary classification, and associated test characteristics (sensitivity and specificity).

For a given cut-off, the proportion of the negative distribution with concentrations higher than the cut-off defines specificity of the test (high proportion implies low specificity), while the proportion of the positive distribution with concentrations lower than the cut-off defines sensitivity of the test. Technically, both sensitivity and specificity are calculated using cumulative density functions of the negative (specificity) and positive distributions (sensitivity) [1]. Figure S6




Figure S6. Sensitivity, specificity, and Youden index. Shown are the estimated sensitivity (red), specificity (blue), and Youden index (gray, superposed on top of sensitivity and specificity) as function of the cut-off concentration for seropositivity. Shown are 1,000 samples from the posterior distribution.

shows the test characteristics and the Youden index ($Se + Sp - 1$) as function of the cut-off. For low values of the cut-off, sensitivity of the test is high, at the price of a low specificity. Conversely, at high values of the cut-off, specificity of the test is high, at the price of low sensitivity. At intermediate values both sensitivity and specificity are reasonably high, and the Youden index is maximal.

Table S3. Test characteristics for cut-off that maximizes the Youden index or that selects for high test specificity ($Sp = 0.999$). Shown are posterior medians with 95% credible intervals.

Scenario	cut-off (95%CrI)	Se (95%CrI)	Sp (95%CrI)	Youden (95%CrI)
Youden	-0.56 (-0.67, -0.44)	0.979 (0.965, 0.987)	0.989 (0.985, 0.993)	0.97 (0.95, 0.98)
Sp	0.04 (0.0, 0.08)	0.943 (0.910, 0.966)	0.999	0.94 (0.91, 0.97)

In Table S3 we show test characteristics for two specific scenarios. The first takes cut-offs that maximize the Youden index. Here, the estimated optimal cut-off is -0.56 (95%CrI: -0.67- -0.44) and the estimated maximal Youden index is 0.97 (94%CrI: 0.95-0.98). This cut-off, however, is not useful in practice as expected seroprevalence is low ($< 10\%$), and control of the false positive rate is more important than control of the false negative rate. Therefore, in a second scenario we aimed at a specificity of 0.999. Such specificity can be reached with the test, at a cut-off of 0.04 and a sensitivity of 0.943 (which is really good for such specificity!). In the following and in the main text we have opted for a cut-off of 0.04.

Figure S7 presents the results as a Receiver Operating Characteristic (ROC) diagram (blue lines), together with true and false positive rates at the cut-off of 0.04 (red dots). Variation in the false positive rate is minimal ($\widehat{Sp} = 0.9990$, 95%CrI : 0.9987 – 0.9992), while estimated sensitivity is still high ($\widehat{Se} = 0.944$, 95%CrI : 0.910–0.967). Estimated Youden index is 0.94 (95%CrI : 0.91–0.97).




Figure S7. Receiver operator characteristic (ROC) diagram. Shown are the false positive rates ($1 - Sp$) and true positive rates (Se) for 1,000 samples from the posterior distribution (blue). Also shown are the false and true positive rates for cut-off of 0.04 ($\log(AU)/mL$) (1.04 AU/mL)(red).

Finally, Figure S8 shows the posterior distribution of test sensitivity at a cut-off of 0.04 ($\log(\text{AU})/\text{mL}$). Mean and standard deviation of the distribution are 0.942 and 0.0151, respectively. These values can be incorporated in Rogan-Gladen-type corrections for estimating true prevalence from observed apparent prevalence in binary classification [10, 11].




Figure S8. Posterior distribution of the true positive rate (sensitivity) when the cut-off is set at 0.04 ($\log(\text{AU})/\text{mL}$) (1.04 AU/mL). Shown is a histogram of 1,000 samples from the posterior distribution. Mean and standard deviation of the distribution are 0.942 and 0.0151, respectively.

8 Logistic regression

The main text provides main results and interpretation of the analyses with logistic regression using the binary classification described in the above. Below we provide additional results on the regional estimates of seroprevalence (Figure S9), as well as the age-specific estimates of the unadjusted odd ratios for seropositivity derived from the univariable model (Figure S10).




Figure S9. Estimates of seroprevalence by municipal health service area. Shown are estimates of (random effect) logistic regression based on the above binary classification, including sample weights and Rogan-Gladen bias correction [10].




Figure S10. Estimates of the unadjusted odd ratios for seropositivity as function of age (see main text for adjusted odds ratios). The estimate is based on (random-effects) univariable logistic regression. Also shown is the 95% confidence envelope. Reference age is 12 years (odds ratio = 1).

References

- [1] P. F. Teunis, M. T. Fonville, D. D. Döpfer, I. A. Eijck, V. Molina, E. Guarnera, and J. W. van der Giessen. Usefulness of sero-surveillance for *Trichinella* infections in animal populations. *Vet Parasitol*, 159(3-4):345–349, Feb 2009.
- [2] A. Steens, S. Waaijenborg, P. F. Teunis, J. H. Reimerink, A. Meijer, M. van der Lubben, M. Koopmans, M. A. van der Sande, J. Wallinga, and M. van Boven. Age-dependent patterns of infection and severity explaining the low impact of 2009 influenza A (H1N1): evidence from serial serologic surveys in the Netherlands. *Am J Epidemiol*, 174(11):1307–1315, Dec 2011.
- [3] M. van Boven, J. van de Kasstele, M. J. Korndewal, C. H. van Dorp, M. Kretzschmar, F. van der Klis, H. E. de Melker, A. C. Vossen, and D. van Baarle. Infectious reactivation of cytomegalovirus explaining age- and sex-specific patterns of seroprevalence. *PLoS Comput Biol*, 13(9):e1005719, Sep 2017.
- [4] G. den Hartog, R. M. Schepp, M. Kuijer, C. GeurtsvanKessel, J. van Beek, N. Rots, M. P. G. Koopmans, F. R. M. van der Klis, and R. S. van Binnendijk. SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence. *J Infect Dis*, 222(9):1452–1461, 10 2020.
- [5] J. D. M. Verberk, R. A. Vos, L. Mollema, J. van Vliet, J. W. M. van Weert, H. E. de Melker, and F. R. M. van der Klis. Third national biobank for population-based seroprevalence studies in the Netherlands, including the Caribbean Netherlands. *BMC Infect Dis*, 19(1):470, May 2019.
- [6] Eric R A Vos, Gerco den Hartog, Rutger M Schepp, Patricia Kaaijk, Jeffrey van Vliet, Kina Helm, Gaby Smits, Alienke Wijmenga-Monsuur, Janneke D M Verberk, Michiel van Boven, Rob S van Binnendijk, Hester E

- de Melker, Liesbeth Mollema, and Fiona R M van der Klis. Nationwide seroprevalence of sars-cov-2 and identification of risk factors in the general population of the netherlands during the first epidemic wave. *Journal of Epidemiology & Community Health*, 2020.
- [7] P. H. Eilers and B. D. Marx. Flexible smoothing with b -splines and penalties. *Statist. Sci.*, 11(2):89–121, 05 1996.
- [8] S. Lang and A. Brezger. Bayesian p-splines. *Journal of Computational and Graphical Statistics*, 13, 03 2004.
- [9] B. Carpenter, A. Gelman, M. Hoffman, D. Lee, B. Goodrich, M. Betancourt, M. Brubaker, J. Guo, P. Li, and A. Riddell. Stan: A probabilistic programming language. *Journal of Statistical Software, Articles*, 76(1):1–32, 2017.
- [10] W. J. Rogan and B. Gladen. Estimating prevalence from the results of a screening test. *Am J Epidemiol*, 107(1):71–76, Jan 1978.
- [11] Z. Lang and J. Reiczigel. Confidence limits for prevalence of disease adjusted for estimated sensitivity and specificity. *Prev Vet Med*, 113(1):13–22, Jan 2014.